Eylea
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Originally approved in 2011, aflibercept is a vascular endothelial growth factor (VEGF) inhibitor.
Background: To report a case of a peripheral exudative haemorrhagic retinopathy (PEHR) associated with treatment response to…
Background:
Age-releated macular degeneration (AMD) is a very prevalent disease worldwide and it is the most common cause of…
The authors report, for the first time, an association between large colloid drusen (LCD) and choroidal neovascularization in a…
« Off-label » administration of certain drugs has represented a common practice in medicine in the latest decades. Even if this…
The FDA has accepted for standard review Regeneron Pharmaceuticals Inc.’s supplemental Biologics License Application (sBLA) of…
The Japanese Ministry of Health, Labour, and Welfare has approved Regeneron Pharmaceuticals Inc.’s aflibercept (Eylea) injection…
New molecular entity: Aflibercept once-monthly intravitreal injection is FDA approved to treat patients with wet (neovascular…